Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 3.82 EUR 1.17% Market Closed
Market Cap: 656.9m EUR
Section:
 

Relative Value

The Relative Value of one VLA stock under the Base Case scenario is 8.58 EUR. Compared to the current market price of 3.82 EUR, Valneva SE is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VLA Relative Value
Base Case
8.58 EUR
Undervaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
61
vs Industry
70
Median 3Y
2.1
Median 5Y
2.5
Industry
7.9
Forward
3.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-7.2
Median 5Y
-10.9
Industry
24
Forward
-13.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4
Median 5Y
-2.8
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-3.5
Industry
23.7
More Details
3.3
P/B
P/B
Price to Book Value
3.3
vs History
66
vs Industry
31
Median 3Y
3.3
Median 5Y
4.6
Industry
3.4
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
63
vs Industry
60
Median 3Y
2.1
Median 5Y
2.3
Industry
8.3
Forward
3.4
More Details
4.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.3
vs History
87
vs Industry
45
Median 3Y
5.7
Median 5Y
7.2
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
8
Median 3Y
-7.5
Median 5Y
-12.9
Industry
6.7
Forward
-11.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
4
Median 3Y
-6.6
Median 5Y
-9
Industry
7.2
Forward
-8.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-2.6
Industry
8.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-2.6
Industry
6.7
More Details
2
EV/IC
EV/IC
Enterprise Value to IC
2
vs History
58
vs Industry
48
Median 3Y
1.8
Median 5Y
2.1
Industry
5.7
More Details

Multiples Across Competitors

VLA Competitors Multiples
Valneva SE Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Valneva SE
PAR:VLA
620.4m EUR 2.1 -7.3 -15.9 -8.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
399.6B USD 6.7 170.2 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
177.5B USD 4.9 25.3 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD 9.9 31.5 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.6B USD 5.3 16.5 15.7 17.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.4B USD 18.8 1 385.9 182.8 221.7
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
47.2B EUR 15.2 35.8 62 63.7
P/S Multiple
Revenue Growth P/S to Growth
FR
Valneva SE
PAR:VLA
Average P/S: 3 098 350.9
2.1
33%
0.1
FR
Pharnext SCA
OTC:PNEXF
34 079 720.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 067.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
6%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.8
46%
0.4
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.2
49%
0.3
P/E Multiple
Earnings Growth PEG
FR
Valneva SE
PAR:VLA
Average P/E: 212.9
Negative Multiple: -7.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 385.9
N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.8
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Valneva SE
PAR:VLA
Average EV/EBITDA: 43
Negative Multiple: -15.9
38%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
182.8
N/A N/A
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
62
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Valneva SE
PAR:VLA
Average EV/EBIT: 49.7
Negative Multiple: -8.9
95%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
221.7
N/A N/A
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
63.7
N/A N/A

See Also

Summary
VLA intrinsic value, competitors valuation, and company profile.
DCF Valuation
VLA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VLA stock valuation using valuation multiples.
Wall Street Estimates
VLA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VLA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.